DE69637063D1 - Oral verfügbare wachstumshormon-sekretagoge - Google Patents

Oral verfügbare wachstumshormon-sekretagoge

Info

Publication number
DE69637063D1
DE69637063D1 DE69637063T DE69637063T DE69637063D1 DE 69637063 D1 DE69637063 D1 DE 69637063D1 DE 69637063 T DE69637063 T DE 69637063T DE 69637063 T DE69637063 T DE 69637063T DE 69637063 D1 DE69637063 D1 DE 69637063D1
Authority
DE
Germany
Prior art keywords
growth hormone
hormone secretagogue
available growth
oral available
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637063T
Other languages
English (en)
Other versions
DE69637063T2 (de
Inventor
Philip A Carpino
Dasilva Paul Jardine
Bruce A Lefker
John A Ragan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69637063(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69637063D1 publication Critical patent/DE69637063D1/de
Application granted granted Critical
Publication of DE69637063T2 publication Critical patent/DE69637063T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69637063T 1995-12-28 1996-12-04 Oral verfügbare wachstumshormon-sekretagoge Expired - Lifetime DE69637063T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US946995P 1995-12-28 1995-12-28
US9469P 1995-12-28
PCT/IB1996/001353 WO1997024369A1 (en) 1995-12-28 1996-12-04 Growth-hormone secretagogues

Publications (2)

Publication Number Publication Date
DE69637063D1 true DE69637063D1 (de) 2007-06-14
DE69637063T2 DE69637063T2 (de) 2008-02-07

Family

ID=21737850

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637063T Expired - Lifetime DE69637063T2 (de) 1995-12-28 1996-12-04 Oral verfügbare wachstumshormon-sekretagoge

Country Status (43)

Country Link
US (7) US6110932A (de)
EP (1) EP0869968B1 (de)
JP (2) JP3511382B2 (de)
KR (1) KR100320167B1 (de)
CN (1) CN1113895C (de)
AP (2) AP756A (de)
AR (2) AR004367A1 (de)
AT (1) ATE361314T1 (de)
AU (1) AU716934B2 (de)
BG (1) BG64055B1 (de)
BR (1) BR9612465B1 (de)
CA (1) CA2241725C (de)
CO (1) CO4480108A1 (de)
CZ (1) CZ293423B6 (de)
DE (1) DE69637063T2 (de)
DK (1) DK0869968T3 (de)
EG (1) EG24195A (de)
ES (1) ES2285715T3 (de)
GT (1) GT199600100A (de)
HN (1) HN1996000085A (de)
HR (1) HRP960618B1 (de)
HU (1) HUP9901246A3 (de)
IL (4) IL124449A (de)
IS (1) IS4758A (de)
MA (1) MA26415A1 (de)
MX (1) MX9805157A (de)
MY (1) MY135727A (de)
NO (1) NO325135B1 (de)
NZ (1) NZ322172A (de)
OA (1) OA10702A (de)
PE (1) PE30398A1 (de)
PL (1) PL186916B1 (de)
PT (1) PT869968E (de)
RS (1) RS49926B (de)
SA (1) SA97170581B1 (de)
SI (1) SI0869968T1 (de)
SK (1) SK285678B6 (de)
TN (1) TNSN96172A1 (de)
TR (1) TR199801233T2 (de)
TW (1) TW432073B (de)
UA (1) UA66754C2 (de)
WO (1) WO1997024369A1 (de)
ZA (1) ZA9610858B (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
CN100378118C (zh) 1997-04-15 2008-04-02 Csir公司 具有食欲抑制剂活性的药物组合物
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
DE69837264T2 (de) * 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6893877B2 (en) * 1998-01-12 2005-05-17 Massachusetts Institute Of Technology Methods for screening substances in a microwell array
BR9906975A (pt) 1998-01-16 2000-10-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
ID27027A (id) * 1998-06-03 2001-02-22 Pfizer Prod Inc 2-aminopiridin yang mengandung substituen cincin lebur
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
EP1085867A1 (de) * 1998-06-16 2001-03-28 Pfizer Products Inc. Therapeutische kombinationen aus (selektive) estrogen-rezeptor modulatoren (serm) und wachstumshormonsekretionsförderer (ghs) zur behandlung von muskelskelett-gebrechlichkeit
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
CA2341649A1 (en) * 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
DE59903490D1 (de) 1998-09-11 2003-01-02 Schmidmaier Gerhard Biologisch aktive implantate
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
EP1486498A1 (de) * 1998-11-23 2004-12-15 Pfizer Products Inc. Verfahren und Zwischenprodukte für Sekretionsfördermittel für Wachstumshormone
US6297380B1 (en) 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
CA2362290A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
JP4644402B2 (ja) * 1999-07-26 2011-03-02 ベイラー カレッジ オブ メディスン 超高活性ブタ成長ホルモン放出ホルモン類似体
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
EP1113007A1 (de) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
WO2001047558A1 (fr) * 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Medicaments protegeant les nerfs
US20020151040A1 (en) * 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
US7332271B2 (en) * 2000-02-18 2008-02-19 Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
EP1132388A3 (de) * 2000-03-09 2004-03-03 Pfizer Products Inc. Metaboliten von Hexahydropyrazolo[4,3-c]pyridinen
EP1149583A3 (de) * 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
DOP2001000154A (es) * 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
AU6497701A (en) 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
EP1181933A3 (de) * 2000-06-29 2002-04-10 Pfizer Products Inc. Verwendung von wachstumshormonsekretion-fördernden mitteln zur appetit erholung
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
EP1192943A3 (de) * 2000-09-28 2002-11-27 Pfizer Products Inc. Verwendung von Sekretionsfördermitteln für Wachstumshormone in Verbindung mit Körpertraining
EP1330306A2 (de) * 2000-10-10 2003-07-30 BioTrove, Inc. Vorrichtung zum testen, synthese und lagerung sowie verfahren zur herstellung, verwendung und handhabung
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) * 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
WO2003087069A2 (en) * 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US8277753B2 (en) 2002-08-23 2012-10-02 Life Technologies Corporation Microfluidic transfer pin
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
US20060094108A1 (en) * 2002-12-20 2006-05-04 Karl Yoder Thermal cycler for microfluidic array assays
EP1608952B1 (de) * 2002-12-20 2016-08-10 Life Technologies Corporation Assay vorrichtung und verfahren unter verwendung von mikrofluiden matrixstrukturen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) * 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7129561B2 (en) * 2003-11-19 2006-10-31 International Business Machines Corporation Tri-metal and dual-metal stacked inductors
WO2005089945A1 (en) 2004-03-12 2005-09-29 Biotrove, Inc. Nanoliter array loading
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
CA2561801A1 (en) * 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
US7381728B2 (en) 2004-07-28 2008-06-03 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
US20060105453A1 (en) * 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
KR20130048793A (ko) * 2004-08-12 2013-05-10 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을 촉진하는 방법
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1944301A4 (de) 2005-10-27 2012-01-04 Msd Kk Neue benzoxathiinderivate
JP4371164B2 (ja) 2005-11-10 2009-11-25 萬有製薬株式会社 アザ置換スピロ誘導体
KR20080075530A (ko) * 2005-11-21 2008-08-18 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 그렐린, 그 유도체 또는 ＧＨＳ-Ｒ1ａ에 작용하는 물질을유효 성분으로 포함하는 피부 수복 촉진 치료제
US8273702B2 (en) * 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2012809B1 (de) * 2006-03-10 2013-05-22 Ipsen Pharma Verwendung eines ghrelin-agonisten zur erhöhung der katabolischen wirkung einer glukokortikoidbehandlung
AU2007294124A1 (en) * 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18F labeled agents
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008047544A1 (fr) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Dérivé diarylcétimine
EP2074135A2 (de) * 2006-10-02 2009-07-01 Bayer Schering Pharma AG Siliziumderivate für die pet-bilddarstellung
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
EP2118080B1 (de) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
MX2009009291A (es) * 2007-03-01 2009-12-14 Bayer Schering Pharma Ag Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo.
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
EP2002835A1 (de) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolopyridinderivate als NADPH-Oxidasehemmer
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2168602A4 (de) * 2007-06-12 2014-10-29 Inst Pharm & Toxicology Amms Situsspezifische pegylierte lineare lachs-calcitonin-derivate
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2301936A1 (de) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamin-diarylketoximid-derivat
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2166009A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2166010A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2165707A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2305679A1 (de) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazolindionderivate als NADPH-Oxidasehemmer
EP2361911A1 (de) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolopiperidinderivate als NADPH-Oxidasehemmer
EP2361912A1 (de) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolopiperidinderivate als NADPH-Oxidasehemmer
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102762564B (zh) 2010-02-26 2015-09-30 拉夸里亚创药株式会社 用于治疗恶病质的葛瑞林受体激动剂
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA025380B1 (ru) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013175805A1 (en) * 2012-05-25 2013-11-28 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
ES2959427T3 (es) 2012-09-27 2024-02-26 Elanco Animal Health Incorporated Composiciones farmacéuticas para el tratamiento de la inapetencia
WO2014065341A1 (ja) 2012-10-24 2014-05-01 第一三共株式会社 筋萎縮性側索硬化症治療剤
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
KR102221002B1 (ko) * 2013-05-28 2021-02-26 라퀄리아 파마 인코포레이티드 다형체
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX2017001408A (es) * 2014-08-05 2017-05-10 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina.
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
TW201625613A (zh) * 2014-10-31 2016-07-16 拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
BR112019007543A2 (pt) 2016-10-14 2019-07-02 Tes Pharma S R L inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI55343C (fi) * 1971-05-11 1979-07-10 Sandoz Ag Foerfarande foer framstaellning av nya, blodtryckssaenkande 3-hydrazinopyrido(4,3-c)pyridazinderivat
DE2221808C2 (de) * 1972-05-04 1985-06-20 Sandoz-Patent-GmbH, 7850 Lörrach Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
IL107836A (en) * 1992-12-11 1998-01-04 Merck & Co Inc Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them
JP3670690B2 (ja) * 1993-10-04 2005-07-13 トーアエイヨー株式会社 ３−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤
PL314003A1 (en) * 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
EP0739204A4 (de) * 1993-11-09 2000-03-15 Merck & Co Inc Piperidine, pyrrolidine und hexahydro-1h-azepine unterstützen die freisetzung des wachstumshormon
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ID18218A (id) * 1995-01-27 1998-03-19 Novo Nordisk As Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
AU4534696A (en) * 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) * 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1997006803A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
WO1997007117A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
JP2001213800A (ja) 2001-08-07
AP9600881A0 (en) 1997-01-31
US6313140B1 (en) 2001-11-06
NO982991D0 (no) 1998-06-26
HUP9901246A2 (hu) 1999-08-30
BR9612465B1 (pt) 2010-08-10
US6110932A (en) 2000-08-29
EP0869968A1 (de) 1998-10-14
CZ293423B6 (cs) 2004-04-14
IL124449A (en) 2004-06-01
PL327634A1 (en) 1998-12-21
ATE361314T1 (de) 2007-05-15
AR004367A1 (es) 1998-11-04
HRP960618B1 (en) 2007-12-31
KR100320167B1 (ko) 2003-11-14
MA26415A1 (fr) 2004-12-20
JP3511382B2 (ja) 2004-03-29
CN1113895C (zh) 2003-07-09
DE69637063T2 (de) 2008-02-07
ZA9610858B (en) 1998-06-23
TNSN96172A1 (fr) 2005-03-15
HN1996000085A (es) 1997-06-18
DK0869968T3 (da) 2007-09-10
YU70296A (en) 1999-11-22
SK285678B6 (sk) 2007-06-07
BG102533A (en) 1999-09-30
UA66754C2 (en) 2004-06-15
KR19990076846A (ko) 1999-10-25
CA2241725A1 (en) 1997-07-10
SI0869968T1 (sl) 2007-08-31
GT199600100A (es) 1998-06-12
NO325135B1 (no) 2008-02-04
IL138910A0 (en) 2001-11-25
US6306875B1 (en) 2001-10-23
US6124264A (en) 2000-09-26
US6482825B2 (en) 2002-11-19
IS4758A (is) 1998-05-26
AP9901555A0 (en) 1999-06-30
MY135727A (en) 2008-06-30
AU716934B2 (en) 2000-03-09
AR052506A2 (es) 2007-03-21
US20020049196A1 (en) 2002-04-25
MX9805157A (es) 1998-10-31
TW432073B (en) 2001-05-01
HRP960618A2 (en) 1998-04-30
US6107306A (en) 2000-08-22
OA10702A (en) 2001-05-07
AP860A (en) 1999-08-06
IL138909A0 (en) 2001-11-25
PL186916B1 (pl) 2004-03-31
NO982991L (no) 1998-08-26
PE30398A1 (es) 1998-07-21
AP756A (en) 1999-08-06
IL138911A0 (en) 2001-11-25
EG24195A (en) 2008-10-14
SA97170581B1 (ar) 2006-03-15
ES2285715T3 (es) 2007-11-16
BG64055B1 (bg) 2003-11-28
CO4480108A1 (es) 1997-07-09
RS49926B (sr) 2008-09-29
NZ322172A (en) 2000-08-25
US6278000B1 (en) 2001-08-21
HUP9901246A3 (en) 1999-11-29
SK87498A3 (en) 1999-08-06
CZ199598A3 (cs) 1999-05-12
EP0869968B1 (de) 2007-05-02
BR9612465A (pt) 1999-07-13
WO1997024369A1 (en) 1997-07-10
CN1206422A (zh) 1999-01-27
TR199801233T2 (xx) 1998-10-21
CA2241725C (en) 2002-06-18
PT869968E (pt) 2007-07-11
IL138911A (en) 2007-07-24
IL124449A0 (en) 1998-12-06
AU7585096A (en) 1997-07-28
JPH11501945A (ja) 1999-02-16

Similar Documents

Publication Publication Date Title
DE69637063D1 (de) Oral verfügbare wachstumshormon-sekretagoge
PT926158E (pt) Hormona paratiroide cristalina
FI973749A0 (fi) Suun kautta annosteltava 2-metyylitienobentsodiatsepiinivalmiste
DE59509539D1 (de) Zwischenwirbel-implantat
FR2729291B1 (fr) Implant rachidien
ID18218A (id) Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
EP0741578A4 (de) Menschliches wachstumshormon
DE69726608D1 (de) Schraubbares implantat
ID25000A (id) Sekretagogues hormon pertumbuhan
HUP0001164A3 (en) Cyclic depsipeptide pf1022 derivatives
DK0882066T3 (da) Peptidderivater
DE29509294U1 (de) Mundeinsatz
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
DE69612084T2 (de) Wachstumsfaktor-Analoga
HUP0000490A3 (en) Cyclic peptide derivatives
NO981051D0 (no) Peptidderivater
FI972968A (fi) Menetelmiä kasvuhormonivaikutusten estämiseksi
EE9800147A (et) Kasvuhormooni sekretagoogi polümorfsed vormid
FR2732890B1 (fr) Implant dentaire impacto-visse
ZA967973B (en) Human growth hormone variants
KR970015941U (ko) 구두골
SE9203175D0 (sv) Growth hormone
BR1100812A (pt) Peptìdeo
SE9504467D0 (sv) Peptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: RAQUALIA PHARMA INC., AICHI-KEN, JP